the pathogens Legionella spp., Mycoplasma spp. and intracellular S. aureus.
Introduction
The effect of an antibiotic on those pathogens that replicate intracellularly is dependent upon its capacity to penetrate phagocytes, and on the suitability of the intracellular environment for the expression of its activity. 1 Neither -lactams nor aminoglycosides are active against phagocytosed bacteria because their intracellular concentrations remain low. [2] [3] [4] Macrolides, quinolones, rifampicin, teicoplanin and clindamycin accumulate readily in phagocytes [5] [6] [7] [8] but some may not be as effective as expected; for example, clindamycin has little activity against intracellular cocci even though it is readily taken up by macrophages. [9] [10] [11] In addition, drugs that penetrate macrophages poorly, e.g. -lactams, demonstrate activity in MIC assays but are clinically ineffective. Consequently, susceptibility testing using intracellular models may be used to complement conventional MIC assays.
Staphylococcus aureus, although not an obligate intracellular pathogen, is capable of survival within phagocytes, and this determines its virulence. 12, 13 The pathogens Legionella spp., Mycoplasma pneumoniae and Chlamydia spp. are commonly implicated in community-acquired pneumonia.
Quinupristin/dalfopristin is a combination of the semisynthetic streptogramins quinupristin and dalfopristin in a ratio of 30:70 (w/w). Quinupristin and dalfopristin are water-soluble derivatives of pristinamycin I A (a group B streptogramin) and pristinamycin II A (a group A streptogramin), respectively, making quinupristin/dalfopristin the first injectable streptogramin antibiotic. Individually, in vitro, the two components are bacteriostatic; however, in combination synergy occurs, producing bacteriostatic activity that is at least eight-fold higher than the sum of the individual components, as well as bactericidal activity. [14] [15] [16] Quinupristin/dalfopristin also displays considerable invitro antibacterial activity against a wide range of Grampositive cocci, Gram-negative respiratory pathogens and Gram-positive anaerobic organisms. (Table I) . 17 In a separate study with conventional MIC methods, the in-vitro activity of quinupristin/dalfopristin against Legionella pneumophila serogroups 1-8 is shown in Table I (Table  II) . 20 Quinupristin/dalfopristin was active in vitro against erythromycin-resistant strains of M. fermentans and M. hominis (MIC 90 0.5 and 2 mg/L, respectively) and doxycycline-resistant strains of U. urealyticum (MIC 90 1 mg/L). Against doxycycline-susceptible and -resistant strains of U. urealyticum, the initial MIC 90 (0.5 mg/L; measured after 18 h) for quinupristin/dalfopristin was half that of the final MIC 90 (1 mg/L; measured after 40 h). 21 Quinupristin/dalfopristin displayed bacteriostatic activity similar to that of erythromycin and doxycycline against M. pneumoniae and M. genitalium (quinupristin/ dalfopristin MIC 90 0.1 and 0.05 mg/L, respectively; 
In-vitro activity of quinupristin/dalfopristin against intracellular Staphylococcus aureus
Quinupristin/dalfopristin was actively taken up into murine macrophages, and incubation of the drug (10 MIC: 2.5 mg/L) with macrophages containing ingested S. aureus resulted in a bactericidal effect in which approximately 70% of the intracellular bacteria were killed within 120 min. 21 For quinupristin/dalfopristin, intracellular concentrations reached 50 and 30 times the extracellular concentrations, respectively, showing how readily these compounds penetrate into cells. In addition, removal of extracellular quinupristin/dalfopristin resulted in the release of the intracellular drugs until equilibrium was reached, indicating that the two compounds may be delivered in high concentrations at the site of infection.
Conclusions
The data reviewed here indicate that quinupristin/dalfopristin is active in vitro against Legionella and Mycoplasma species, as well as S. aureus. Quinupristin/dalfopristin has good in-vitro inhibitory activity against all Legionella species, particularly L. pneumophila (against which it is slightly more active than erythromycin), with L. micdadei being least susceptible to quinupristin/dalfopristin. The activity of quinupristin/dalfopristin, an injectable preparation, suggests that it might be suitable for use in the treatment of legionella infections.
Mycoplasma pneumoniae, M. hominis and U. urealyticum are significant human pathogens, and all are inhibited by quinupristin/dalfopristin. At present, the other mycoplasmas tested, M. fermentans and M genitalium, have undefined roles as human pathogens. Quinupristin/dalfopristin is active against all mycoplasma strains in vitro (and is one of the most active compounds tested), even those resistant to erythromycin and doxycycline. The activity displayed by quinupristin/dalfopristin against the pathogens Legionella spp. and Mycoplasma spp. suggests that this drug may prove effective in the treatment of lower respiratory tract infections caused by these pathogens.
Staphylococcus aureus can survive within phagocytes and this, together with its increasing resistance to multiple antibiotics, underlies the importance of developing new intracellularly active antibiotics. Quinupristin/dalfopristin is bactericidal against intracellular staphylococci, and thus may be useful as an alternative to vancomycin in the treatment of severe infections caused by multiply resistant staphylococci.
As quinupristin/dalfopristin is actively taken up by macrophages the combination is delivered in high concentrations at the site of infection. This, together with the reported in-vitro bactericidal activity of quinupristin/dalfopristin against intracellular S. aureus, suggests the drug may prove valuable in the treatment of some respiratory tract infections, irrespective of their severity. 
